Welcome to our dedicated page for Blade Air Mobility SEC filings (Ticker: BLDE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BLDE SEC filings page on Stock Titan provides access to the regulatory history of Blade Air Mobility, Inc., which has since changed its name to Strata Critical Medical, Inc. and now trades on Nasdaq under the symbol SRTA, as disclosed in a Form 8-K dated August 29, 2025. These filings document the company’s evolution from a technology-powered air mobility platform combining passenger and medical operations into a focused medical logistics business.
Among the key documents are multiple Current Reports on Form 8-K. One Form 8-K filed on August 5, 2025 furnishes a press release announcing financial results for the quarter ended June 30, 2025 under Item 2.02 (Results of Operations and Financial Condition). Another Form 8-K filed on August 1, 2025 describes an Equity Purchase Agreement under Item 1.01, outlining the terms under which a subsidiary of Joby Aviation agreed to acquire Blade’s Passenger business, including the structure of cash or stock consideration, earn-out provisions, and related non-compete and commercial arrangements.
A subsequent Form 8-K filed on August 29, 2025 reports the completion of the Passenger business sale, details the consideration received in Joby Aviation common stock and potential additional amounts, and explains the company’s name change to Strata Critical Medical, Inc. and ticker change to SRTA. That filing also discusses related agreements, such as a restrictive covenant agreement and a commercial agreement giving Joby a role in providing certain medical transport services, and notes amendments to the company’s charter and bylaws.
Later 8-K filings under the Strata Critical Medical name, such as those dated September 16, 2025 and November 10, 2025, describe material events including the acquisition of Keystone Perfusion Services, LLC and the release of quarterly financial results. Together, these filings show how the company has shifted toward mission critical logistics and medical services for hospitals and healthcare providers.
On Stock Titan, users can review these BLDE-linked filings with AI-powered summaries that highlight the main terms of material agreements, changes in corporate structure, and key financial disclosures. Real-time updates from EDGAR, along with structured access to Forms 8-K and other reports, help investors quickly understand how Blade’s historical regulatory record connects to the current Strata Critical Medical (SRTA) listing.
Strata Critical Medical (formerly Blade) reported Q3 2025 results highlighting a strategic pivot to healthcare services. Revenue from continuing operations reached $49,298 (vs. $36,062 a year ago), while operating loss narrowed to $5,622. The quarter’s net income of $57,416 was driven by discontinued operations following the Passenger business sale.
On August 29, Strata sold its Passenger business to a Joby Aviation subsidiary for consideration valued at $75,357 in Joby shares and later sold those shares for net proceeds of $70,163. The company may receive up to an additional $35,000 based on performance and retention targets, plus up to $10,000 in indemnity holdbacks. On September 16, Strata acquired Keystone Perfusion Services for $109,963 in cash and 3,434,609 shares valued at $16,828, adding $69,067 of goodwill and $42,600 of identifiable intangibles.
Cash and cash equivalents were $22,753 and short‑term investments were $53,165 as of September 30, 2025. Basic and diluted EPS were $0.70, reflecting a continuing operations loss of $0.12 and discontinued operations income of $0.81. Shares outstanding were 86,366,526 as of November 3, 2025.
Strata Critical Medical, Inc. furnished a Form 8-K to announce it issued a press release with financial results for the third quarter ended September 30, 2025. The press release is attached as Exhibit 99.1 and incorporated by reference.
The disclosure is provided under Item 2.02, Results of Operations and Financial Condition, and is designated as furnished, not filed, under the Exchange Act.
Strata Critical Medical, Inc. reported insider equity activity by its Chief Accounting Officer, Amir Cohen. On 10/31/2025, Cohen acquired 41,786 shares at $0 upon certification of performance criteria tied to previously granted PSUs. On 11/03/2025, 20,497 shares were withheld by the company at $5.03 to cover taxes related to that vesting. Following these transactions, Cohen directly owned 121,342 shares.
Strata Critical Medical, Inc. (SRTA) reported insider equity changes by Co‑CEO, General Counsel, and Director Melissa M. Tomkiel. On 10/31/2025, she acquired 208,929 shares of Class A common stock at $0, reflecting certification of performance-based restricted stock units (PSUs). On 11/03/2025, 106,659 shares were disposed under code F at $5.03, representing shares withheld to satisfy tax obligations upon PSU vesting. Following these transactions, she beneficially owns 1,372,642 shares, held directly.
Strata Critical Medical, Inc. (SRTA): Director and Co-CEO/CFO William A. Heyburn reported equity changes on Form 4. On 10/31/2025, he acquired 181,072 shares of Class A common stock at $0 upon the Compensation Committee’s certification of performance criteria for PSUs granted on March 8, 2024. Following this, his beneficial ownership was 1,486,569 shares (direct).
On 11/03/2025, 100,133 shares were disposed of at $5.03 under transaction code “F,” reflecting shares withheld by the issuer to satisfy tax withholding obligations related to the PSU vesting. After these transactions, his beneficial ownership stood at 1,386,436 shares (direct).
Strata Critical Medical, Inc. reported an insider transaction by Co-CEO, General Counsel, and Director Melissa M. Tomkiel. On 10/22/2025, she exercised stock options (transaction code M) for 55,556 shares of Class A common stock at $0.18 per share and acquired the same number of shares.
After the transaction, she directly beneficially owned 1,270,372 shares. Her remaining derivative holdings included 304,738 stock options outstanding, originally exercisable from 05/07/2021 and expiring on 07/28/2030.
Strata Critical Medical (SRTA) reported an insider transaction: Co‑CEO and General Counsel Melissa M. Tomkiel exercised stock options (code M) for 55,555 Class A shares at $0.18 on 10/10/2025.
Following the transaction, she beneficially owned 1,214,816 shares directly, and held 360,294 stock options outstanding. The option grant was originally exercisable from 05/07/2021 and expires 07/28/2030.
Strata Critical Medical, Inc. completed the acquisition of Keystone Perfusion Services, LLC on September 16, 2025. The buyer paid a base Purchase Price of $124 million (subject to adjustment), with payment structured eighty percent in cash and twenty percent in Strata common stock, plus up to $23 million of contingent consideration tied to performance over the next 12, 24 and 36 months.
The Purchase Price can be adjusted downward or upward by up to $12.4 million based on Keystone's 2025 adjusted EBITDA relative to specified thresholds. At Closing, after adjustments and expenses, Seller received roughly 88% cash and 12% stock. Strata issued 3,434,607 shares in reliance on exemptions from registration and obtained representation and warranty insurance as primary recourse for certain breaches. The filing includes a standard cautionary note on forward-looking statements and lists customary surviving reps, warranties and covenants.
Robert S. Wiesenthal, a director of Strata Critical Medical, Inc. (ticker: SRTA), reported a grant of 40,607 restricted stock units (RSUs) on 08/29/2025 that will be settled in common stock upon vesting. The RSUs are valued at $0 in the filing and 100% of these RSUs vest on the date of the company's 2026 Annual Meeting of Stockholders. The filing states the reporting person beneficially owns 5,275,662 shares following the reported transaction as direct ownership. The filing also discloses that, effective September 2, 2025, the issuer amended the terms of previously granted unvested RSUs totaling 886,886 and 33,591 units to add an additional performance-related vesting condition, and those units are no longer included in the beneficial ownership total until the performance condition is met. The Form 4 is signed by an attorney-in-fact on behalf of Mr. Wiesenthal.
Amir Cohen, Chief Accounting Officer and director of Strata Critical Medical, Inc. (SRTA), reported a grant of 11,844 fully vested restricted stock units (RSUs) on 08/29/2025. The RSUs vest and will be settled in shares of the issuer's Class A common stock at no cash price ($0). Following this transaction, Mr. Cohen beneficially owns 103,760 shares. The RSU grant is effective upon completion of the issuer's previously disclosed sale of its Passenger business to Joby Aero, Inc. under an Equity Purchase Agreement dated August 1, 2025. The Form 4 was signed by attorney-in-fact Melissa M. Tomkiel on 09/03/2025.
FAQ
What is the current stock price of Blade Air Mobility (BLDE)?
What is the market cap of Blade Air Mobility (BLDE)?
